Technology | October 17, 2007

EZ-EM to Spotlight Injectors, VoLumen Oral Contrast

EmpowerCTA injector offers both E-Z-EM’s patented extravasation detection accessory (EDA) and a saline chase. Modular CT injector features air embolism protection, on-the-fly flow rate manipulation, easy syringe loading and arming at the injector. IRiS software tracks: patient ID, creatinine values, GFR, consumable utilization, total contrast filled/injected/wasted, type of contrast, EDA activation status and number of EDA-identified extravasations.

Also featured, the E-Z-EM EmpowerMR injector reportedly provides virtually no injector RF in the scanner room, consistent flow rate delivery, pressure performance on demand, improved productivity and compatibility up to 7T environments.
EmpowerMR employs a hydraulic control system instead of the shielded electrical control components used by most other MR injector systems. EmpowerMR has no shielded iron motors, piezoelectric motors and electrically active motor control circuitry adjacent to the scanner, which significantly minimizes the prospect of electrical interference with the scanner's magnetic field. EmpowerMR is also not battery operated, and links to its electrical supply by a single pass-through cable that does not require special shielding.

E-Z-EM’s VoLumen is a low Hounsfield value oral contrast for MDCT and PET/CT studies designed to overcome the limitations of water and other higher-density positive oral contrasts. It reportedly allows for the simultaneous investigation of all organs, vasculature and surrounding structures of the abdominal/pelvic region and is used in CT Enterography (CTE) for the diagnosis/evaluation of Crohn's disease and other inflammatory bowel disease. It also reportedly minimizes X-ray attenuation, reducing isotope uptake artifacts in PET/CT. VoLumen does not convert to glucose, so it does not interfere with the injection of the glucose-based radioactive contrasts.

Related Content

Guerbet, IBM Watson Health Partner on Artificial Intelligence for Liver Imaging
News | Clinical Decision Support | July 10, 2018
Guerbet announced it has signed an exclusive joint development agreement with IBM Watson Health to develop an...
Imaging agent helps predict success of lung cancer therapy
News | Oncology Diagnostics | March 08, 2018
March 8, 2018 – Doctors contemplating the best therapy for...
OptiStar Elite injector
Feature | Contrast Media Injectors | March 07, 2018 | Grand View Research Inc.
The global contrast media injectors market is expected to reach $1.4 billion by 2025, growing at a compound annual...
TriHealth in Cincinnati

TriHealth in Cincinnati.

Sponsored Content | Case Study | Contrast Media Injectors | March 06, 2018
The continuing search for advantages to improve workflow has radiology departments constantly searching for new...
Guerbet Presents Contrast&Care Injection Management Solution at ECR 2018
News | Contrast Media | February 28, 2018
February 28, 2018 — Guerbet will present its new Contrast&Care application, as well as other...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns. Gadolinium deposition in the brain has raised concerns about Gadolinium toxicity.

Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns, as seen in this MRI.

Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
ACR Introduces New Contrast Reaction Card
News | Contrast Media | February 07, 2018
The American College of Radiology (ACR) introduced a new contrast reaction card that summarizes important steps to be...
Bracco Diagnostics' MultiHance Contrast Agent Earns Expanded Approval for Pediatric MRI
News | Contrast Media | January 30, 2018
Bracco Diagnostics Inc. announced the labeling of its contrast agent MultiHance has obtained U.S. Food and Drug...
Study Finds No Evidence that Gadolinium Causes Neurologic Harm

MR images through, A, C, E, basal ganglia and, B, D, F, posterior fossa at level of dentate nucleus. Images are shown for, A, B, control group patient 4, and the, C, D, first and, E, F, last examinations performed in contrast group patient 13. Regions of interest used in quantification of signal intensity are shown as dashed lines for globus pallidus (green), thalamus (blue), dentate nucleus (yellow), and pons (red).

News | Contrast Media | January 11, 2018
January 11, 2018 — There is no evidence that accumulation in the brain of the element gadolinium speeds cognitive dec
Overlay Init